The length of the document below is: 21 page(s) long
The self-declared author(s) is/are:
Author: Steven M. Lieberman, Paul B. Ginsburg
The subject is as follows:
Subject: Lowering costs of drugs for payers and patients by increasing price transparency for generic drugs
The original URL is: LINK
The access date was:
Access date: 2019-04-01 09:42:39.613924
Please be aware that this may be under copyright restrictions. Please send an email to admin@pharmacoengineering.com for any AI-generated issues.
Loading...
Reload document 
Open in new tab The content is as follows:
WOULD PRICE TRANSPARENCY FOR
GENERIC DRUGS LOWER COSTS FOR
PAYERS AND PATIENTS?
Steven M. Lieberman and Paul B. GinsburgThe Brookings InstitutionJune 2017ABSTRACT
billion and accounting for more than 10 percent of overall U.S. health care spending. Almost 9 of 10 retail
(brand) drugs typically have much more expensive ingredients that account for most of the cost at retail
The U.S. system for selling prescription medicines involves multiple parties, differs markedly for generic
extent that a lack of information about actual generic drug costs leads to excessive reimbursement.
proposed policy to generate information on actual average prices paid by retail pharmacies to acquire generic
collusive pricing. We propose a strategy to make actual average generic drug price information selectively
Please note all content on this page was automatically generated via our AI-based algorithm (BishopKingdom ID: 0Ams3vIEFOOVwuaypovQ). Please let us know if you find any errors.